Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.36 |
| ▸ | CALML3 | P27482 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402993 | 0.89 | MAOA (0.38) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3095610 | 0.83 | MAOA (0.58) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL18403035 | 0.82 | MAOA (0.41) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL21555906 | 0.82 | MAOA (0.40) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL21555918 | 0.79 | MAOA (0.39) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL21555902 | 0.79 | L3MBTL1 (0.41) | MAOACALML3LMNA | |
| SCHEMBL18403006 | 0.78 | ATM (0.39) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL10196342 | 0.78 | MAOA (0.55) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL3084973 | 0.78 | MAOA (0.55) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL18402996 | 0.78 | MAOA (0.42) | MAOAMAOBCALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885MAOB 1093/4885S1PR1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.